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Summary
A single injection of regadenoson can be used instead of
an adenosine infusion to produce coronary vasodilata-
tion and demonstrate myocardial ischemia during first-
pass perfusion cardiac MRI.
Background
Cardiac stress MR perfusion imaging requires an MRI
compatible infusion pump for the administration of ade-
nosine or a non-MRI compatible pump housed in the
control room or beyond the 10-Gauss line. Regadenoson
is a recently FDA-approved A2A receptor agonist that
can be given intravenously in a single bolus. It has been
shown to provide diagnostic information regarding myo-
cardial ischemia on SPECT-MPI.
Methods
42 patients (34 M, 55 yrs, range 41-73 yrs) with a rever-
sible myocardial perfusion defect on SPECT-MPI under-
went a cardiac perfusion MRI within 7 days of the
SPECT-MPI. MR exams consisted of short and long axis
cine steady state free precession (SSFP) imaging,
matched gradient-recalled echo (GRE) GRAPPA tem-
poral parallel acquisition (TPAT) first-pass stress perfu-
sion (TR 2.3 msec, TE 1.1 msec, 80*256 matrix, 1.4 x
3.1mm2), and delayed contrast-enhanced (DCE) T1
GRE imaging. First-pass perfusion images were obtained
30 seconds after regadenoson 400 micrograms adminis-
tered in a single IV bolus and during power injection of
0.075 mmol/Kg of gadobenate dimeglumine at 5 mL/sec
IV followed by normal saline flush. DCE imaging was
obtained 10 minutes after injection of an additional
0.025 mmol/Kg of contrast agent.
Results
All but one patient tolerated the regadenoson MR
examination. One patient had chest pain shortly after
imaging, and received aminophylline, with resolution of
symptoms. MR showed ischemia in 33/42 subjects. In 8
subjects the MR perfusion exam was normal. Five of
these 8 patients underwent clinically-ordered invasive
cardiac catheterization (ICA) within 3-18 days of the
MRI examination. ICA showed no stenoses, suggesting
SPECT attenuation artifact. The other 3/8 patients had
no MACE within 30-180 days. In one patient, SPECT
demonstrated ischemia only, while MRI showed infarct
only in the same segment.
Conclusions
Regadenoson can be used in cardiac MR perfusion ima-
ging to demonstrate ischemia. MRI perfusion imaging
may be useful in differentiating attenuation artifact from
true disease.
Funding
Funding for this project was provided by Astellas. Addi-
tional research support provided by Siemens Medical
Systems.
Author details
1Metrohealth Medical Center, Cleveland, OH, USA.
2Washington University
School of Medicine, St. Louis, MO, USA.
3St. Luke’s Cardiovascular
Consultants, Kansas City, MO, USA.
4Siemens Medical Systems, Malvern, PA,
USA.
Published: 1 February 2012
doi:10.1186/1532-429X-14-S1-P11
Cite this article as: Lyons et al.: Feasibility of detecting myocardial
ischemia using first-pass contrast MRI and regadenoson. Journal of
Cardiovascular Magnetic Resonance 2012 14(Suppl 1):P11.
2Washington University School of Medicine, St. Louis, MO, USA
Full list of author information is available at the end of the article
Lyons et al. Journal of Cardiovascular Magnetic Resonance 2012, 14(Suppl 1):P11
http://www.jcmr-online.com/content/14/S1/P11
© 2012 Lyons et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.